3. Xiang NJ, Li XY, Ren RQ, et al. Assessing change in avian influenza A (H7N9) virus infections during the fourth epidemic -- China, September 2015-August 2016. Morb Mortal Wkly Rep, 2016, 65(49): 1390-1394.
[4]
4. Zhou L, Ren R, Yang L, et al. Sudden increase in human infection with avian influenza A (H7N9) virus in China, September-December 2016. Western Pac Surveill Response J, 2017, 8(1): 6-14.
6. Tan KX, Jacob SA, Chan KG, et al. An overview of the characteristics of the novel avian influenza A H7N9 virus in humans. Front Microbiol, 2015, 6(140): 140-151.
12. Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis, 2014, 58(8): 1095-1103.
[13]
13. Yang ZF, Mok CK, Liu XQ, et al. Clinical, virological and immunological features from patients infected with re-emergent avian-origin human H7N9 influenza disease of varying severity in Guangdong province. PLoS One, 2015, 10(2): e117846.
[14]
14. Wu W, Shi D, Fang D, et al. A new perspective on C-reactive protein in H7N9 infections. Int J Infect Dis, 2016, 44(C): 31-36.
16. Poddar B, Gurjar M, Singh S, et al. Reduction in procalcitonin level and outcome in critically ill children with severe sepsis/septic shock-A pilot study. J Crit Care, 2016, 36(2016): 230-233.
[17]
17. Leung YH, To MK, Lam TS, et al. Epidemiology of human influenza A(H7N9) infection in Hong Kong. J Microbiol Immunol Infect, 2015, 2(50): 183-188.
[18]
18. Cao B, Gao H, Zhou B, et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med, 2016, 44(6): e318-e328.
[19]
19. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet, 2013, 381(9885): 2273-2279.
[20]
20. Smee DF, Hurst BL, Wong MH, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res, 2010, 88(1): 38-44.
[21]
21. Zhang Y, Gao H, Liang W, et al. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infect Dis, 2016, 16(1): 76-84.
[22]
22. Pizzorno A, Abed Y, Rhéaume C, et al. Oseltamivir-zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res, 2014, 105(3): 54-58.
